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Abstract
Introduction: Epithelial to mesenchymal transition (EMT) is considered an essential process in the metastatic
cascade. EMT is characterised by upregulation of vimentin, Twist, Snail, Slug and Sip1 among others. Metastasis is
also associated with the presence of circulating tumour cells (CTCs) and disseminated tumour cells in the blood
and bone marrow, respectively, of breast cancer patients, but the expression of EMT markers in these cells has not
been reported so far.
Methods: The expression of Twist and vimentin in CTCs of 25 metastatic and 25 early breast cancer patients was
investigated by using double-immunofluorescence experiments in isolated peripheral blood mononuclear cell cytospins
using anti-cytokeratin (anti-CK) anti-mouse (A45-B/B3) and anti-Twist or anti-vimentin anti-rabbit antibodies.
Results: Among early breast cancer patients, vimentin-and Twist-expressing CK
+ CTCs were identified in 77% and 73%
of the patients, respectively, and in 100% of the patients with metastatic breast cancer for both markers (P = 0.004 and
P = 0.037, respectively). Among patients with early disease, 56% and 53% of the CK
+ CTCs were double-stained with
vimentin and Twist, and the corresponding values for metastatic patients were 74% and 97%, respectively (P =0 . 0 0 5
and P = 0.0001, respectively). The median expression of CK
+vimentin
+ and CK
+Twist
+ cells per patient in metastatic
patients was 98% and 100%, and in an adjuvant chemotherapy setting the corresponding numbers were 56% and
40.6%, respectively. Triple-staining experiments revealed that all CK
+Twist
+ or CK
+vimentin
+ cells were also CD45
-,
confirming their epithelial origin. Immunomagnetic separation of CTCs and triple-immunofluorescence with anti-CK/
anti-Twist/anti-vimentin antibodies demonstrated that both mesenchymal markers could be coexpressed in the same
CK
+ cell, since 64% of the total identified CTCs were triple-stained. There was a significant correlation (P = 0.005)
between the number of CTCs expressing Twist and vimentin within the same setting.
Conclusions: CTCs expressing Twist and vimentin, suggestive of EMT, are identified in patients with breast cancer.
The high incidence of these cells in patients with metastatic disease compared to early stage breast cancer
strongly supports the notion that EMT is involved in the metastatic potential of CTCs.
Introduction
Metastasis is associated with the presence of peripheral
blood circulating tumour cells (CTCs) and bone marrow
disseminated tumour cells (DTCs) in patients with
breast cancer [1,2]. In fact the presence of CTCs before
the initiation and after the completion of adjuvant
chemotherapy is associated with poor clinical outcome
[3-5]. In metastatic breast cancer, the assessment of
CTCs before and shortly after the initiation of che-
motherapy is also predictive of progression-free and
overall survival [6,7], and prognosis seems to depend on
the detection of CTCs rather than DTCs [8]. The pre-
sence of chromosomal alterations confirmed the malig-
nant nature of CTCs [9,10]. Nevertheless, only some of
them are capable of promoting metastasis [11]. There-
fore, further molecular characterisation of CTCs is
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any medium, provided the original work is properly cited.essential to understanding their metastatic potential, as
well as for the identification of additional markers
related to patients’ prognosis.
The metastatic process consists of distinct steps,
including tumour growth, angiogenesis, tumour cell
detachment, epithelial to mesenchymal transition
(EMT), intravasation, survival within blood and lympha-
tic vessels and embolisation, extravasation, mesenchymal
to epithelial transition, formation of micrometastasis
and, finally, growth of macrometastasis [12]. ΕΜΤ is a
process whereby epithelial cells lose their epithelial char-
acteristics and acquire a mesenchymal phenotype. EMT
increases the metastatic and invasive potential of these
cells [13]. Downregulation of epithelial markers such as
cytokeratin and E-cadherin and upregulation of
mesenchymal markers such as vimentin, N-cadherin and
cadherin 11 characterise the EMT process. Usually, inhi-
bition of E-cadherin expression leads to induction of N-
cadherin expression, which has been associated with
tumour invasiveness [14-16]. Transforming growth fac-
tor b as well as transcription factors such as Twist,
Snail, Slug and Sip1 have a regulatory role in EMT.
Twist is a transcriptional repressor of the E-cadherin
gene [12,17]. Increased expression of Twist has been
demonstrated in many types of tumour cells, such as
melanoma, osteosarcoma, T cells (Sézary syndrome) and
gastric, prostate and breast cancer [12,18-23]. The gene
expression profile of immunomagnetically isolated DTCs
has shown elevated expression of Twist in the enriched
fragment compared to that in healthy volunteers [24,25].
Twist expression in breast cancer cells has been shown
to result in resistance to paclitaxel through binding to
Akt promoter and enhancement of its transcriptional
activity [26], as well as resistance to other microtubule-
targeting agents such as vincristine [27,28]. Upregulation
of Twist in cancer cells increases vascular endothelial
growth factor (VEGF) gene expression [21,29], while
hypoxia-inducible factor 1a (HIF-1a) regulates the
expression of Twist by binding directly to the hypoxia
response element in the Twist proximal promoter
[30,31]. We have recently shown that VEGF and HIF-
1a, as well as phosphorylated Akt, are expressed in
CTCs of most metastatic breast cancer patients [32,33];
therefore, it was interesting to further investigate the
expression of Twist in CTCs of breast cancer patients.
Vimentin is an intermediate filament normally
expressed in mesenchymal cells and is involved in the
migration of epithelial cells during development [34].
The expression of vimentin in cancer cells is believed to
enhance migration and invasiveness [35]. Expression of
vimentin is characteristic of epithelial cells undergoing
the EMT process and is related to reduced expression of
E-cadherin and upregulation of N-cadherin [16,36],
while increased expression of vimentin in breast carci-
nomas is correlated with poor prognosis [37]. Moreover,
the simultaneous expression of vimentin and cytokeratin
in tumour cells is associated with poorer survival in
breast cancer patients [38]. Recent studies have demon-
strated that vimentin is expressed in DTCs of breast
cancer patients and tumour cell lines [39,40]; however,
there have been no studies in which the expression of
both EMT markers (Twist and vimentin) was evaluated
in CTCs. Therefore, the aim of the present study was to
investigate the expression of these molecules in CTCs of
patients with early and metastatic breast cancer.
Materials and methods
Patient samples and cytospin preparation
A longitudinal trial for the study of micrometastatic dis-
ease in breast cancer has been underway in our institu-
tion since 1996. Peripheral blood samples are obtained
from patients who provide their written informed con-
sent as part of the routine evaluation before the initia-
tion of and at the end of adjuvant treatment, as well as
prior to and after the completion of each chemotherapy
line in patients with metastatic disease. Frozen RNA
samples and peripheral blood mononuclear cell (PBMC)
cytospins are prepared simultaneously and stored at -80°
C until use. In the current trial, samples taken from
patients with adjuvant or metastatic breast cancer were
screened for cytokeratin (CK)-19 mRNA expression
[41,42] by RT-PCR. Fifty CK-19 mRNA-positive patients
(25 with early stage breast cancer and 25 with metastatic
breast cancer) were enrolled in the present study. We
used archived slides from these patients because we
wanted to have the same blood samples for real-time
RT-PCR and immunocytochemistry. Ten healthy female
blood donors were also included as a control group. All
blood samples were obtained at the middle of venipunc-
ture after the first 5 mL of blood were discarded. These
precautions were undertaken to avoid contamination of
the blood samples with epithelial cells from the skin
during sample collection. All patients and healthy volun-
teers gave their written informed consent to participate
in the study, which has been approved by the Ethics and
Scientific Committees of our institution.
The volume of blood drawn from each patient was 20
mL each for immunofluorescence and RT-PCR experi-
ments and 20 mL for immunomagnetic isolation.
PBMCs were isolated by Ficoll-Hypaque density gradient
centrifugation (d = 1,077 g/mol) at 1,800 rpm for 30
minutes. PBMCs were washed three times with PBS and
centrifuged at 1500 rpm for 10 minutes. Aliquots of
250,000 cells were cytocentrifuged at 2,000 rpm for 2
minutes on glass slides. Cytospins were dried up and
stored at -80°C. Four to five slides from each patient
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6 PBMCs
per patient were scanned.
Cell cultures
In control experiments, we used the human cervical
adenocarcinoma cell line HeLa. HeLa cells express
Twist and vimentin and have been proposed as a posi-
tive control by the antibody’s data sheet. The HeLa ade-
nocarcinoma cells (American Type Culture Collection,
Manassas, VA, USA) were cultured in 1:1 (vol/vol)
DMEM (Gibco-BRL, Grand Island, NY) supplemented
with 10% foetal bovine serum (FBS) (Gibco-BRL), 2
mmol L-glutamine (Gibco-BRL) and 50 mg/mL penicil-
lin/streptomycin (Gibco-BRL). Cells were maintained in
a humidified atmosphere of 5% CO2 and 95% room air.
Subcultivation of all cell lines was performed using
0.25% trypsin and 5 mmol ethylenediaminetetraacetic
acid (EDTA) (Gibco-BRL). All experiments were per-
formed during the logarithmic growth phase 15 to 20
hours prior to the experiments. HeLa cells were spiked
in blood obtained from healthy volunteers, and cytos-
pins were prepared afterward with Ficoll-Hypaque den-
sity gradient centrifugation as per patients’ samples.
Double-immunofluorescence confocal laser-scanning and
ARIOL scanning microscopy
The presence of CK-positive cells in PBMC cytospin
preparations was investigated using the mouse A45-B/
B3 antibody (detecting CK8, CK18 and CK19) (Micro-
met, Munich, Germany). Control experiments for the
sensitivity and the specificity of this antibody have been
reported previously [32,33,43]. The cytomorphological
criteria proposed by Meng et al. [44] (for example, high
nuclear/cytoplasmic ratio, larger cells than white blood
cells) were used to characterise a CK-positive cell as a
CTC.
Cytospins from the same patients were double-stained
for Twist/CK (Abcam, Cambridge, UK) and vimentin/
CK (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
in double-staining experiments [43]. Specific staining
can easily be distinguished by double-immunofluores-
cence because of the differential intracellular distribu-
tion of the examined molecules compared to nonspecific
staining as reported by Fehm et al. [45]. For double-
staining experiments, PBMC cytospins were fixed with
3% paraformaldehyde. Permeabilisation of the cell mem-
brane was performed with 0.5% Triton for 10 min and
blocking with PBS/1% BSA overnight. Subsequently,
slides were stained for cytokeratin with the A45-B/B3
anti-mouse antibody along with the corresponding sec-
ondary fluorescein isothiocyanate (FITC) fluorochrome.
Slides were then stained with Twist or vimentin anti-
rabbit antibodies and afterward with the corresponding
anti-rabbit secondary antibodies for 45 minutes.
Negative controls were performed for all the primary
antibodies by omitting the corresponding primary anti-
body and adding the secondary immunoglobulin G
(IgG) isotype antibody. Finally, 4’,6-diamidino-2-pheny-
lindole (DAPI) antifade reagent (Invitrogen, Carlsbad,
CA, USA) was added to each sample for nuclear stain-
ing. Slides were analysed using a confocal laser-scanning
microscope (Leica Lasertechnik, Heidelberg, Germany)
and the ARIOL CTC automated image analysis system
(Genetix, New Milton, Hampshire, UK).
Triple immunofluorescence
Triple-immunofluorescence for CK/Twist/CD45, CK/
vimentin/CD45 and CK/Twist/vimentin was also per-
formed in samples processed by immunomagnetic
separation to be enriched in CTCs. Cells were initially
fixed using 4% formaldehyde for 15 minutes at room
temperature. Permeabilisation was achieved with 0.1%
Triton X-100 for 5 minutes at room temperature. After
blocking with PBS supplemented with 10% (vol/vol) FBS
for 30 minutes, cells were incubated with the corre-
sponding antibodies for 45 minutes each. Zenon tech-
nology (FITC-conjugated IgG1 antibody) (Molecular
Probes/Invitrogen, Carlsbad, CA, USA) was used for CK
detection with the A45-B/B3 antibody. Zenon antibodies
were prepared within 30 minutes of being used.
Twist was detected using anti-mouse antibody
(Abcam) labelled with Alexa Fluor 633 (Molecular
Probes/Invitrogen) or Twist anti-rabbit (Cell Signaling
Technology, Boston, MA, USA) labelled with Alexa
Fluor 555 (Molecular Probes, Carlsbad, CA, USA). Posi-
tive and negative controls for Twist anti-rabbit are
shown in Figure 1A, while positive and negative controls
for the Twist anti-mouse antibody are presented in
Additional file 1. Vimentin was detected using anti-rab-
bit antibody (Santa Cruz Biotechnology) labelled with
Alexa Fluor 555, and positive and negative controls are
shown in Additional file 1. CD45 was detected with an
anti-mouse antibody (Dako, Carpinteria, CA, USA)
labelled with Alexa Fluor 633. Cells incubated with the
different antibodies were postfixed with 4% (vol/vol) for-
maldehyde in PBS for 15 minutes at room temperature.
Finally, cells were stained with DAPI conjugated with
antifade reagent.
Immunomagnetic separation of CTCs
Α negative selection procedure was used for the isola-
tion of CTCs according to the method described by
Naume et al. [46]. A quantity of 100 μL of Dynal CEL-
Lection beads (Invitrogen)c o a t e dw i t ha n t i - C D 4 5
monoclonal antibody were added to 1 × 10
7P/mL
PBMCs in PBS/0.1% BSA/2 mM EDTA. After incuba-
tion for 30 minutes at 4°C, the supernatant was trans-
ferred into FBS-coated tubes and cells were
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slides. The same number of cells was centrifuged at
1,500 rpm for 5 minutes, and the pellet was stored at
-80°C for RNA extraction. The specificity and the sensi-
tivity of this method has been described previously [33].
CD45 immunomagnetic depletion was performed for
the purpose of triple-staining experiments only to enrich
the samples with CTCs.
Results
Twist and vimentin expression in HeLa cells and PBMCs
of normal blood donors
HeLa cell cytospins spiked in blood from healthy volun-
teers and processed as per patient samples were used as
positive controls for the detection of Twist and vimen-
tin. Positive and negative controls for Twist, vimentin
and CK are shown in Figure 1.
Figure 1 Twist and vimentin expression in HeLa cells spiked in blood of normal volunteers. ARIOL system images of HeLa cells spiked in
the blood of normal volunteers. (A) Row I: Positive control for Twist. HeLa cells were stained with pan-CK A45-B/B3 antibody/secondary FITC
anti-mouse antibody (green)/Twist anti-rabbit antibody/Alexa Fluor 555 anti-rabbit antibody (orange). Row II: Negative control for Twist. Cells
were stained with pan-CK A45-B/B3 antibody/FITC anti-mouse (green) and Alexa Fluor 555 IgG isotype antibody. Cell nuclei were stained with
DAPI (blue). Original magnification, x400. (B) Row I: Positive control for vimentin. Cells were stained with pan-CK A45-B/B3 antibody/FITC anti-
mouse antibody (green)/vimentin anti-rabbit antibody/Alexa Fluor 555 anti-rabbit antibody (orange). Row II: Negative control for vimentin. Cells
were stained with pan-CK A45-B/B3 antibody/FITC anti-mouse antibody (green) and Alexa Fluor 555 IgG isotype antibody. Row III: Negative
control for pan-CK. Cells were stained with FITC IgG isotype antibody/vimentin anti-rabbit antibody/Alexa Fluor 555 anti-rabbit antibody (orange).
Cell nuclei were stained with DAPI (blue). Original magnification, x400. ARIOL system = automated image analysis system; CK = cytokeratin; FITC
= fluorescein isothiocyanate; HeLa = patient with cervical adenocarcinoma from which the cell line was derived; IgG = immunoglobulin G; DAPI
=4 ’,6-diamidino-2-phenylindole.
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investigated in PBMC cytospins from 10 healthy blood
donors. Both molecules were found to be expressed
spontaneously in PBMCs, but there were no double-
positive cells (CK
+Twist
+ or CK
+vimentin
+) in healthy
volunteers.
Twist and vimentin expression on CTCs of early stage and
metastatic breast cancer patients
Twenty-five patients with metastatic breast cancer and
twenty-five patients with early breast cancer who had
detectable CK-19 mRNA-positive cells by RT-PCR were
enrolled in this study. The concordance between RT-
PCR and immunocytochemistry was 100% in metastatic
breast cancer patients and 88% in early breast cancer
patients. The clinicopathological characteristics of these
patients are presented in Table 1.
We investigated the expression of Twist and vimentin
on CTCs using PBMC cytospin preparations from these
patients. The presence of CK
+ cells was confirmed by
immunofluorescence in all patients with metastatic dis-
ease and in 22 of 25 patients with early stage disease.
Double-staining experiments with pan-CK and Twist
antibodies revealed that all patients with metastatic dis-
ease had detectable double-stained cells and that CK
+/Twist
+ cells could be detected in 16 (72.7%) of 22
patients with early stage breast cancer (P = 0.037) (Fig-
ure 2A, graph I, and Table 2). Additionally, the propor-
tion of double-positive CTCs was lower in patients with
early stage breast cancer than in patients with metastatic
breast cancer (53% versus 97%, respectively; P = 0.0001)
(Figure 2A, graph II). Confocal laser-scanning micro-
scopy and ARIOL system microscopy revealed that
Twist was located both in the cytoplasm and in the
nuclei of CTCs (Figures 2B, graph I; Figures 3 and 4;
and Additional file 2). The median number of CTCs per
patient expressing Twist
+/CK
+ was 100% (range, 33% to
100%) in patients with metastatic disease and 40.6%
(range, 12% to 100%) in patients with early stage breast
cancer (Figure 2A, graph III). Nineteen patients with
metastatic breast cancer (76%) had only double-positive
cells (Twist
+CK
+), while in early breast cancer patients
only six (27%) of twenty-two CK
+ patients had exclu-
sively Twist
+CK
+ cells (P = 0.0001) (Table 2).
We subsequently assessed the expression of vimentin
in CTCs of the same cohort of patients. Vimentin was
also expressed in CTCs in 100% and 77% of patients
with metastatic and early stage disease, respectively (P =
0.004) (Figure 2A, graph I, and Table 2). Furthermore,
the proportion of double-positive CTCs was lower in
patients with early stage cancer than in those with meta-
static disease (56% versus 74%; P =0 . 0 0 5 )( F i g u r e2 A ,
graph II). In addition, the median proportion of double-
positive CTCs per patient with early stage and
metastatic disease was 56% (range, 21.8% to 100%) and
98% (range, 16.7% to 100%), respectively (Figure 2A,
graph III). In 12 (48%) of 25 patients with metastatic
disease, all the CTCs were double-positive (vimentin
+
CK
+)c o m p a r e dw i t ho n l y6( 2 7 % )o f2 2p a t i e n t sw i t h
early disease who had exclusively vimentin
+CK
+ CTCs
Table 1 Patient characteristics
a
Early breast cancer Metastatic breast cancer
Number of patients enrolled =
25
Number of patients enrolled = 25
Age, years Age, years
Median (range), 59 (26 to 76) Median (range), 59 (36 to 83)
ECOG performance status, n
(%)
ECOG performance status, n (%)
0 24 (96%) 0 8 (32%)
1 1 (4%) 1 13 (52%)
2 0 (0%) 2 4 (16%)
Histology, n (%) Histology, n (%)
Ductal 22 (88%) Ductal 20 (80%)
Lobular 3 (12%) Lobular 1 (4%)
Other 0 (0%) Unknown 4 (16%)
Menopausal status, n (%) Menopausal status, n (%)
Premenopausal 8 (32%) Premenopausal 4 (16%)
Perimenopausal 1 (4%) Perimenopausal 1 (4)
Postmenopausal 16 (64%) Postmenopausal 20 (80%)
Hormone receptor status, n
(%)
Hormone receptor status, n (%)
ER-positive/PR-positive 11
(44%)
ER-positive/PR-positive 11 (44%)
ER-positive/PR-negative 6
(24%)
ER-positive/PR-negative 3 (12%)
ER-negative/PR-positive 1 (4%) ER-negative/PR-positive 2 (8%)
ER-negative/PR-negative 7
(28%)
ER-negative/PR-negative 9 (36%)
Tumour size, n (%) Number of disease sites, n (%)
1 to 1.9 cm (T1) 6 (24%) 1 7 (28%)
2 to 5 cm (T2) 16 (64%) 2 9 (36%)
>5 cm (T3) 1 (4%) 3 4 (16%)
Unknown 2 (8%) ≥4 5 (20%)
Tumour grade, n (%) Line of treatment, n (%)
I 2 (8%) First 11 (44%)
II 9 (36%) Second 7 (28%)
III 13 (52%) ≥Third 7 (28%)
Unknown 1 (4%)
Primary breast cancer at presentation, n
(%)
Early 9 (36%)
Positive nodes, n (%) Metastatic 16 (64%)
0 (N0) 11 (44%)
1 to 3 (N1) 9 (36%) Visceral disease, n (%)
4 to 9 (N2) 2 (8%) Yes 13 (52%)
≥10 (N3) 2 (8%) No 12 (48%)
aECOG = Eastern Cooperative Oncology Group; ER = oestrogen receptor; PR =
progesterone receptor.
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scopy and ARIOL system microscopy revealed that the
intracellular distribution of vimentin in CTCs was
almost identical to that of cytokeratin filaments (Figure
2B, graph II; Figures 3 and 4; and Additional file 2).
A statistically significant correlation (Spearman’s r
analysis) was also observed between the number of
CTCs expressing Twist and vimentin in early stage (P =
0.027) and metastatic (P = 0.009) breast cancer patients.
This correlation remained significant even when all
patients were grouped together (P = 0.005).
Triple-immunofluorescence experiments revealed specific
expression of Twist and vimentin in CTCs
As mentioned above, Twist and vimentin expression was
also observed in PBMCs. To confirm that the cells
characterised as CTCs in breast cancer patients were non-
hematopoietic cells presenting ectopic cytokeratin expres-
sion, we performed triple-immunofluorescence
experiments using antibodies against CKs and CD45 along
with antibodies against Twist or vimentin. These experi-
ments were carried out indicatively in five metastatic and
eight early breast cancer patients. Our results revealed that
no CK
+vimentin
+CD45
+ or CK
+Twist
+CD45
+ cells could
be identified in patient samples (Figure 3).
Vimentin and Twist are coexpressed in CTCs of breast
cancer patients
Subsequently, we investigated the possible coexpression
of the examined mesenchymal markers in the same
CTC. After performing CD45
- immunomagnetic separa-
tion in PBMCs isolated from 24 patients with metastatic
Figure 2 Twist and vimentin expression in CTCs of early and metastatic breast cancer patients. (A) Graph I: Quantification of 25 early and
25 metastatic breast cancer patients in whom double-positive cells of each examined molecule were harvested. Graph II: Quantification of
double-positive CTCs/total CTCs for each examined molecule. Graph III: Quantification of median expression per patient for each examined
molecule. (B) Representative ARIOL system images of CTCs in PBMC cytospin. Row I: Cytospin double-stained with monoclonal pan-CK A45-B/B3
(green)/polyclonal Twist anti-rabbit (red) antibodies and DAPI nuclear staining. Original magnification, x400. Row II: Cytospin double-stained with
monoclonal A45-B/B3 (green)/polyclonal vimentin anti-rabbit (red) antibodies and DAPI nuclear staining. Original magnification, x400. ARIOL
system = automated image analysis system; CK = cytokeratin; CTCs = circulating tumour cells; PBMCs = peripheral blood mononuclear cells;
DAPI = 4’,6-diamidino-2-phenylindole.
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a
Early breast cancer Metastatic breast cancer
Patient Vim
+CK
+ Vim
-CK
+ Twist
+CK
+ Twist
-CK
+ Patient Vim
+CK
+ Vim
-CK
+ Twist
+CK
+ Twist
-CK
+
1 64 51 83 100 1 5 0 4 0
2 25 63 29 142 2 45 0 8 0
3 31 111 578 68 3 21 0 7 0
43 52 8 5 3 8 54 2 0 4 0
5 135 199 18 134 5 74 20 45 0
6 100 158 28 170 6 7 7 3 6
7 170 254 89 423 7 7 2 420 0
80 0 7 4 48 2 1 6 9 2 0
9 0 1 71 95 9 10 90 3 0
10 140 4 0 1 10 2 0 2 0
11 22 0 0 0 11 3 15 103 36
12 17 0 74 88 12 67 3 9 1
13 0 4 8 0 13 4 0 0 0
14 0 0 0 3 14 3 3 42 0
15 7 1 0 4 15 1 0 1 0
16 10 3 12 0 16 1 0 1 0
17 0 0 0 0 17 10 2 55 0
18 28 12 0 0 18 325 97 5 7
19 0 0 0 10 19 17 1 13 0
20 0 1 2 0 20 3 0 0 0
21 2 0 13 0 21 2 0 2 0
22 2 0 0 9 22 2 1 2 0
23 306 0 380 0 23 9 0 658 0
24 1 0 0 2 24 192 4 44 0
25 24 0 1 0 25 40 0 80 0
aCTCs = circulating tumour cells; PBMCs = peripheral blood mononuclear cells; Vim = vimentin; CK = cytokeratin.
Figure 3 Triple-immunofluorescence (CK/Twist/CD45, CK/vimentin/CD45) in CTCs. Representative ARIOL system photomicrographs of CTC
cytospin after negative immunomagnetic separation in patients with metastatic breast cancer. (A) Cells were triple-stained with pan-CK A45-B/B3
antibody/Zenon Alexa Fluor 488 (green)/Twist anti-rabbit antibody/Alexa Fluor 555 anti-rabbit antibody (orange) and CD45 anti-mouse/Alexa
Fluor 633 anti-mouse antibody (blue). Original magnification, x400. (B) Cells were triple-stained with pan-CK A45-B/B3 antibody/Zenon-Alexa
Fluor 488 (green)/vimentin anti-rabbit antibody/Alexa Fluor 555 anti-rabbit antibody (orange) and CD45 anti-mouse/Alexa Fluor 633 anti-mouse
antibody (blue). Original magnification, x400. ARIOL system = automated image analysis system; CK = cytokeratin; CTCs = circulating tumour
cells.
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on one slide for each patient. Triple-immunofluores-
cence experiments using anti-pan-CK, anti-Twist and
anti-vimentin antibodies revealed that 16 (64%) of 25
CTCs identified were CK
+Twist
+vimentin
+ and 9 (36%)
of 25 CTCs identified were CK
+Twist
+vimentin
-.N o n e
of the detected CTCs had the CK
+Twist
-vimentin
+ phe-
notype. These results indicate that Twist and vimentin
are coexpressed in a subset of CTCs of metastatic breast
cancer patients (Figure 4).
Discussion
There is increasing evidence that the presence of CTCs
and DTCs is correlated with minimal residual disease or
disease progression in patients with breast cancer.
Nevertheless, the underlying molecular characteristics of
micrometastatic cells associated with the development
of overt metastases remain largely unknown. EMT is a
multistep process that has been suggested to play a key
role in cancer progression and metastasis [12]. Accord-
ingly, CTCs bearing characteristics of an EMT pheno-
type should be actively involved in tumour
dissemination, proliferation and metastasis. Twist is a
transcription factor that, among others, participates in
EMT and is upregulated in many tumour cells
[18-22,47]. In a recent report by Watson et al. [24],
Twist expression was specifically enhanced in a gene
signature obtained from epithelial cell adhesion mole-
cule-enriched bone marrow samples of patients with
breast cancer after neoadjuvant chemotherapy. Twist
also increases VEGF expression, while it is directly regu-
lated by HIF-1a [30,31]. Since we have recently shown
that 62% and 76% of breast cancer patients express
VEGF and HIF-1a, respectively, in their CTCs [33], it
was of interest to identify the potential expression of
this transcription factor in CTCs.
In the present cytomorphological study, we compared
for the first time the expression of Twist and vimentin
in individual CTCs of patients with early stage versus
metastatic breast cancer. For this purpose, we performed
double-staining experiments with the corresponding
antibodies in PBMC cytospin preparations of 25 early
stage and 25 metastatic breast cancer patients. To con-
firm the specificity of our results, we also performed tri-
ple-staining experiments with pan-CK/Twist/CD45 and
pan-CK/vimentin/CD45 antibodies, which revealed that
the hematopoietic antigen CD45 was not expressed in
CK
+/Twist
+ or CK
+/vimentin
+ cells. These findings
clearly indicate that the observed expression of Twist
and vimentin is not confined to hematopoietic cells.
Double-staining experiments revealed that Twist was
expressed in all CK-19 mRNA
+ metastatic patients,
while most of them (76%) had exclusively double-posi-
tive cells (CK
+Twist
+). The median expression per
Figure 4 Coexpression of CK, Twist and vimentin in the same cell. Representative confocal laser-scanning photomicrographs of CTC
cytospin after negative immunomagnetic separation in a patient with metastatic breast cancer. Cells were triple-stained with pan-CK A45-B/B3
antibody/Zenon Alexa Fluor 488 (green)/Twist anti-mouse/Alexa Fluor 633 anti-mouse antibody/vimentin anti-rabbit/Alexa Fluor 555 anti-rabbit
antibody (orange). Original magnification, x600. (A) A CTC expressing CK, Twist and vimentin. (B) A CTC expressing CK and Twist, but not
vimentin. CK = cytokeratin; CTCs = circulating tumour cells.
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Page 8 of 11patient of Twist in CTCs was also high at 100%. Similar
results have also been reported in two recent studies by
Aktas et al. [48] and Mego et al. [49]. In these studies,
EMT markers including Twist were detected in CTCs of
breast cancer patients at lower percentages of 42%.and
57.7%, respectively. This lower level of expression might
be related to the difference in the identification method
or to immunomagnetic enrichment of tumour cells.
Interestingly, when vimentin expression was investi-
gated in the same cohort of patients, it was observed
that, similarly to Twist, vimentin was expressed in CTCs
of all the evaluated patients with metastatic disease, and
the proportion of patients who had exclusively double-
positive cells (CK
+vimentin
+) was also high. The median
percentage of vimentin-expressing CTCs per patient was
98%. Vimentin is an intermediate filament of mesenchy-
mal cells that is commonly used to identify cells under-
going EMT in cancer. In addition, its expression is
associated with increased risk of metastasis and poor
prognosis in breast cancer patients [37,38]. There are
only two previous reports verifying the expression of
vimentin in DTC cell lines and in CTCs [38,50]. In
agreement with these data, the high rate of Twist and
vimentin expression in CTCs observed in our study
implies that mesenchymal markers are highly expressed
in CTCs of metastatic breast cancer patients and
denotes that the majority of these cells are undergoing
the EMT process.
Furthermore, our experiments revealed that CK
+Twist
+ and CK
+vimentin
+ CTCs were also observed in
patients with early stage breast cancer. This observation
suggests that circulating epithelial (CK
+) cells with an
EMT phenotype may be involved in the continuous
tumour spreading in patients with clinically undetectable
metastases. However, the EMT phenotype expression
was significantly lower (P =0 . 0 3 7f o rT w i s ta n dP =
0.004 for vimentin) in early stage cancer patients than
in metastatic breast cancer patients. The median expres-
sion of Twist and vimentin was also significantly lower
(40.6% and 55.6%, respectively) in early stage cancer
patients, but it was extremely variable from patient to
patient (ranges, 11% to 100% and 21% to 100%, respec-
tively). The proportion of double-positive CTCs in early
stage cancer patients was 53% and 56% for Twist and
vimentin, respectively, which was also significantly dif-
ferent from metastatic breast cancer patients (P =
0.0001 and P = 0.05, respectively). These findings clearly
indicate that EMT markers may be expressed in CTCs
of patients with early stage disease, but to a lesser extent
than in patients with metastatic disease. In addition, the
above results imply that the population of CTCs expres-
sing EMT markers predominates during disease progres-
sion or, alternatively, this cell population is selected over
non-EMT-expressing CTCs because of resistance to
therapy. However, this finding should be interpreted
with caution because of the smaller number of CTCs
detected in patients with early stage compared to
advanced disease, which might influence the chance to
find an EMT-like CTC.
A statistically significant correlation between the num-
ber of CTCs expressing Twist and vimentin in patients
with both early stage and metastatic disease was demon-
strated (P = 0.005 and P = 0.027, respectively), suggest-
ing that both biomarkers were simultaneously expressed
in CTCs. This assumption was confirmed by triple-
staining experiments using antibodies against CK, Twist
and vimentin in immunomagnetically isolated CTCs
from 24 patients, which demonstrated that the majority
(64%) of CTCs had the CK
+Twist
+vimentin
+ phenotype.
Nevertheless, 36% of the CTCs were CK
+Twist
+vimen-
tin
-, whereas there were no cells with the CK
+Twist-
vimentin
+ phenotype (Figure 4). These findings indicate
the heterogeneity of CTCs. It is also possible that Twist
expression is a more common phenomenon during
EMT, thus suggesting Twist as a more specific marker
for EMT.
Finally, a differential intracellular distribution for
v i m e n t i na n dT w i s tw a so b s e r v e di nC T C s .V i m e n t i n
was primarily located in the cytoplasm, similarly to the
intracellular distribution of CK (Figures 2, 3, 4). This
observation is in agreement with the findings of pre-
vious reports showing that vimentin filaments follow the
preexisting CK network during EMT progression [51].
Twist showed both cytoplasmic and nuclear localisation
as expected, considering its function as a transcription
factor (Figures 2, 3, 4).
Conclusions
The results of the present study clearly indicate that
EMT markers such as Twist and vimentin are expressed
in CTCs of patients with early stage and metastatic
breast cancer. The variable expression of these mole-
cules in CTCs at different stages of disease implies the
predominance of the EMT phenotype during disease
evolution. This hypothesis is further supported by the
observation that CK
+ CTCs in patients with early stage
breast cancer are more heterogeneous with regard to
the expression of EMT markers, necessitating additional
studies to further elucidate their distinct biological role.
Additional material
Additional file 1: Triple-staining control experiments in HeLa cells.
Triple-staining control experiments in HeLa cells analysed using a
confocal laser-scanning microscope. (I) Representative confocal laser-
scanning photomicrographs of positive controls for Twist anti-mouse
antibody. HeLa cells were stained with pan-CK A45-B/B3 antibody/Zenon
Alexa Fluor 488 (green)/Twist anti-mouse/Alexa Fluor 633 anti-mouse IgG
(blue)/vimentin anti-rabbit antibody/Alexa Fluor 555 anti-rabbit antibody
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Page 9 of 11(red). Original magnification, x500. (II) Negative control for Twist. HeLa
cells stained with pan-CK A45-B/B3 antibody/Zenon Alexa Fluor 488
(green)/Alexa Fluor 633 anti-mouse IgG (blue)/vimentin anti-rabbit
antibody/Alexa Fluor 555 anti-rabbit antibody (red). Original
magnification, x500. (II) Negative control for vimentin. HeLa cells were
stained with pan-CK A45-B/B3 antibody/Zenon Alexa Fluor 488 (green)/
Twist anti-mouse antibody/Alexa Fluor 633 anti-mouse antibody (blue)/
Alexa Fluor 555 IgG isotype antibody (red). Original magnification, x500.
CK = cytokeratin; HeLa = patient with cervical adenocarcinoma, from
which the cell line was derived; IgG, immunoglobulin G.
Additional file 2: Twist and vimentin expression in CTCs of breast
cancer patients. Representative confocal laser-scanning microscopic
images of Twist-or vimentin-expressing CTCs of breast cancer patients. (I)
Representative confocal laser-scanning microscopic images of breast
cancer patients’ cytospin double-stained with monoclonal pan-CK (A45-
B/B3)/Alexa Fluor 488 anti-mouse antibody (green)/polyclonal Twist anti-
rabbit antibody and Alexa Fluor 555 anti-rabbit antibody (red). Original
magnification, x600. (II) Representative images of cytospin double-stained
with monoclonal pan-CK (A45-B/B3)/Alexa Fluor 488 anti-mouse antibody
(green)/polyclonal vimentin anti-rabbit antibody and Alexa Fluor 555
anti-rabbit antibody (red). Original magnification, x600. CK = cytokeratin;
CTCs = circulating tumour cells; FITC = fluorescein isothiocyanate.
Abbreviations
ARIOL system: automated image analysis system; BSA: bovine serum
albumin; CTCs: circulating tumour cells; DMEM: Dulbecco’s modified Eagle’s
medium; DTCs: disseminated tumour cells; ECOG: Eastern Cooperative
Oncology Group; EMT: epithelial-to-mesenchymal transition; FITC: fluorescein
isothiocyanate; HeLa: patient with cervical adenocarcinoma from which the
cell line was derived; PBMCs: peripheral blood mononuclear cells; PBS:
phosphate-buffered saline; RT-PCR: reverse transcriptase polymerase chain
reaction.
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